- Brooklyn ImmunoTherapeutics Inc BTX has announced a publication in Breast Cancer Research, which demonstrates how multiplex immunofluorescence (mIF) may be used to characterize the immunological activity of IRX-2 in early-stage breast cancer.
- IRX-2 is an allogeneic, cell-derived biologic with multiple active cytokine components, including IL-2, that act on various parts of the immune system associated with activation of the entire tumor microenvironment.
- "Multiplex immunofluorescence combined with hierarchical linear modeling resulted in more precise estimates of treatment-related increases in stromal tumor-infiltrating lymphocytes, PD-L1, and other metrics such as CD8+ tumor nest infiltration compared to conventional testing," said principal study investigator David Page.
- The company said that hierarchical linear modeling could mitigate the effects of intratumoral heterogeneity on immune cell count estimations, thus allowing more efficient detection of treatment-related pharmocodynamic effects of an anticancer drug such as IRX-2.
- The paper illustrates that IRX-2 increases immune cell infiltration and PD-L1 expression, suggesting that IRX-2 may hold promise in the combination of PD-L1-targeted therapy in early-stage breast cancer.
- The company is conducting a Phase 2 trial to assess the efficacy and safety of IRX-2 in patients with triple-negative breast cancer.
- Approximately 30 patients in total are expected to be enrolled. The primary efficacy endpoint is pathological complete response rate, evaluated at the time of definitive surgery.
- Price Action: BTX shares are down 5.8% at $30.42 during the market trading session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
